ECOG 2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (RCC)

Study Status

Closed to Enrollment

Study Description

The purpose of this study is to compare the disease-free survivial of patients with locally advanced renal cell carciinoma (kidney cancer) treated with adjuvant sunitinib male vs sorafenib vs placebo after a radical or partial nephrectomy (kidney removal).

Patients will be randomized to either:

  • Arm A: Sunitinib
  • Arm B: sorafenib alone
  • Arm C: placebo

Disease Status and/or Stage

Renal Cell Cancer


Eastern Cooperative Oncology Group

Key Eligibility

  • Must have primary intact RCC, eligible for nephrectomy with curative intent
  • No prior anti-cancer therapy is permitted in either the adjuvant or neoadjuvant setting. This includes metastectomy for renal cell carcinoma or radiation therapy to the renal bed
  • Additional eligibility discussed when you contact the study team

Principal Investigator

David Nanus, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page